European Society for Medical Oncology

Pharma

Novartis, Daiichi, AZ shine in ESMO analysis of cancer approvals

Novartis, Daiichi Sankyo and AstraZeneca emerged as the top drugmakers in an analysis of the clinical value added by new solid tumor cancer medicines.

Kevin Dunleavy Sep 13, 2024 8:06am

ESMO: Searching for the perfect cup of pharma-branded espress-MO

Oct 20, 2023 7:59am

Regeneron, Sanofi won't dethrone Merck in lung cancer: analysts

Sep 24, 2020 10:41am

New cancer drugs carry high price, add little benefit: studies

Sep 27, 2019 12:05am

Can BMS' new Opdivo data uphold its small-cell lung cancer nod?

Dec 13, 2018 12:15pm

Half of doctors are still wary of PARPs: executive

Oct 24, 2018 11:06am